Citation: World Journal of Gastrointestinal Pharmacology and Therapeutics. 9(1):1-7, 2018 Feb 06.Journal: World journal of gastrointestinal pharmacology and therapeutics.Published: 2018ISSN: 2150-5349.Full author list: Choden T; Mandaliya R; Charabaty A; Mattar MC.UI/PMID: 29430322.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Internal Medicine | GastroenterologyActivity type: Journal Article.Medline article type(s): Journal Article | ReviewDigital Object Identifier: https://dx.doi.org/10.4292/wjgpt.v9.i1.1 (Click here)Abbreviated citation: World J Gastrointest Pharmacol Ther. 9(1):1-7, 2018 Feb 06.Abstract: Inflammatory bowel disease has a high prevalence in women of childbearing age and can have a significant impact on pregnancy, from conceiving to carrying the pregnancy. Active disease during pregnancy is known to have negative effects on pregnancy outcomes; therefore, careful monitoring during this period is an important but challenging aspect of care and is crucial as it affects important management decisions. Recent data seems to suggest that endoscopy is a relatively safe procedure during all trimesters of pregnancy. Serum biomarkers such as C-reactive protein and fecal calprotectin are helpful non-invasive markers, but have shown conflicting results for correlation with disease activity in some initial studies. Further work is necessary to establish standard of care monitoring during pregnancy.